Latest Cost Restructuring News

COSOL Limited reports a $7-8 million revenue shortfall in H1 FY26 amid macroeconomic pressures but pivots towards higher-margin Asset Management as a Service contracts and cost efficiencies to stabilize performance.

Vinyl Group Ltd reports a striking 190% revenue surge in FY25 and a record Q1 FY26, setting sights on its first EBITDA-positive quarter by mid-2026.

Excite Technology Services has raised $2.1 million through convertible notes from institutional investors, including key backer Belgravia Strategic Equities, to fund cost restructuring and operational improvements.

MC Mining Limited has appointed Yi (Christine) He as its permanent Managing Director and CEO, cementing leadership ahead of key coal production milestones at the Makhado Project.

RPMGlobal Holdings clarifies the reasons behind withdrawing its FY2025 earnings guidance following the divestment of its Advisory business, providing detailed updates on software segment performance and compliance with ASX disclosure rules.

DGL Group Limited has issued a corrected FY25 financial presentation, revealing lower EBITDA and NPAT figures due to operational challenges and restructuring costs. Despite revenue growth, the company faces a modified audit opinion on inventory and outlines strategic cost-cutting and growth investments.

Atomos Ltd reported a 9% revenue decline to $32.7 million for FY25 but improved its loss after tax by 35%, driven by cost restructuring and tighter expense control amid challenging market conditions.

BSA Limited reported a 65% drop in net profit for FY2025 despite a 12% revenue increase, driven by the loss of key contracts and a significant operational overhaul. The company faces near-term unprofitable trading but maintains a strong cash position as it reshapes its business.

Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.

Xref Limited reported a significantly reduced net loss for FY2025 and a return to positive EBITDA, driven by strategic cost restructuring and a transition to a SaaS business model.

IDP Education’s FY25 results reveal a 14% revenue decline amid a 29% drop in student placement volumes, but strong price growth and cost discipline underpin a multi-year transformation aimed at future profitability.

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.